A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
Phase 1 – testing safety in a small group of people
Conditions:
Patients with advanced malignancies
Sponsor: Novartis Pharma AG
trial.available_in:
БГ
Overview
Trial status: Authorised
Who can participate
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 24 participants
БГ